Is DexCom Stock Underperforming the S&P 500?

San Diego, California-based DexCom, Inc. (DXCM) is a medical device company that designs, develops, and commercializes continuous glucose monitoring (CGM) systems. Valued at $24.8 billion by market cap, the company develops a small implantable device that continuously measures glucose levels in subcutaneous tissue just under the skin and a small external receiver to which the sensor transmits glucose levels at specified intervals. Companies worth $10 billion or more are generally described as “large-cap stocks,” and DXCM perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the medical devices industry. DexCom leads…